



| Recipient Information 1. Recipient Name TRUSTEES OF TUFTS COLLEGE 136 HARRISON AVE BOSTON, MA 02111 2. Congressional District of Recipient 07 3. Payment System Identifier (ID) 1042103634A5 4. Employer Identification Number (EIN) 042103634 5. Data Universal Numbering System (DUNS) 039318308 6. Recipient's Unique Entity Identifier C1F5LNUF7W86 7. Project Director or Principal Investigator Karl Munger, PHD Professor And Chair karl.munger@tufts.edu 617-636-0306 8. Authorized Official Barbara Gardner Barbara.Gardner@tufts.edu 617-636-2473 | Federal Award Information 11. Award Number 5R01AI170633-04 12. Unique Federal Award Identification Number (FAIN) R01AI170633 13. Statutory Authority 42 USC 241 42 CFR 52 14. Federal Award Project Title Regulation of the Human Papillomavirus Life Cycle by the Long Noncoding RNA DINO 15. Assistance Listing Number 93.855 16. Assistance Listing Program Title Allergy and Infectious Diseases Research 17. Award Action Type Non-Competing Continuation 18. Is the Award R&D? Yes | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|--|--|--|---|-----------|--------------------------|-----------|----------------------------|-----------|--------------------------|--|------------|--|--|-----------|---|-----|---|-----------|--|--|---|--|---|-------------|
| Federal Agency Information 9. Awarding Agency Contact Information DEOGRATIUS BUSIMBA Gunza Grants Management Specialist NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES deo.gunza@nih.gov (240) 292-6092 10. Program Official Contact Information Rodolfo M. Alarcon Program Officer NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES rodolfo.alarcon@nih.gov 240-292-0871 | <table border="1" style="width: 100%;"> <tr> <th colspan="2" style="text-align: center;">Summary Federal Award Financial Information</th> </tr> <tr> <td colspan="2" style="background-color: #e6f2ff;">19. Budget Period Start Date 06/01/2026 – End Date 05/31/2027</td> </tr> <tr> <td>20. Total Amount of Federal Funds Obligated by this Action</td> <td style="text-align: right;">\$418,426</td> </tr> <tr> <td> 20 a. Direct Cost Amount</td> <td style="text-align: right;">\$255,955</td> </tr> <tr> <td> 20 b. Indirect Cost Amount</td> <td style="text-align: right;">\$162,471</td> </tr> <tr> <td>21. Authorized Carryover</td> <td></td> </tr> <tr> <td>22. Offset</td> <td></td> </tr> <tr> <td>23. Total Amount of Federal Funds Obligated this budget period</td> <td style="text-align: right;">\$418,426</td> </tr> <tr> <td>24. Total Approved Cost Sharing or Matching, where applicable</td> <td style="text-align: right;">\$0</td> </tr> <tr> <td>25. Total Federal and Non-Federal Approved this Budget Period</td> <td style="text-align: right;">\$418,426</td> </tr> <tr> <td colspan="2" style="border-top: 1px dashed black;"></td> </tr> <tr> <td colspan="2" style="background-color: #e6f2ff;">26. Project Period Start Date 06/01/2023 – End Date 05/31/2028</td> </tr> <tr> <td>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</td> <td style="text-align: right;">\$1,673,704</td> </tr> </table> 28. Authorized Treatment of Program Income Additional Costs 29. Grants Management Officer - Signature Robert Kirker | Summary Federal Award Financial Information | | 19. Budget Period Start Date 06/01/2026 – End Date 05/31/2027 | | 20. Total Amount of Federal Funds Obligated by this Action | \$418,426 | 20 a. Direct Cost Amount | \$255,955 | 20 b. Indirect Cost Amount | \$162,471 | 21. Authorized Carryover | | 22. Offset | | 23. Total Amount of Federal Funds Obligated this budget period | \$418,426 | 24. Total Approved Cost Sharing or Matching, where applicable | \$0 | 25. Total Federal and Non-Federal Approved this Budget Period | \$418,426 | | | 26. Project Period Start Date 06/01/2023 – End Date 05/31/2028 | | 27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period | \$1,673,704 |
| Summary Federal Award Financial Information | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 19. Budget Period Start Date 06/01/2026 – End Date 05/31/2027 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 20. Total Amount of Federal Funds Obligated by this Action | \$418,426 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 20 a. Direct Cost Amount | \$255,955 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 20 b. Indirect Cost Amount | \$162,471 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 21. Authorized Carryover | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 22. Offset | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 23. Total Amount of Federal Funds Obligated this budget period | \$418,426 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 24. Total Approved Cost Sharing or Matching, where applicable | \$0 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 25. Total Federal and Non-Federal Approved this Budget Period | \$418,426 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 26. Project Period Start Date 06/01/2023 – End Date 05/31/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period | \$1,673,704 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 30. Remarks Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system. | | | | | | | | | | | | | | | | | | | | | | | | | | | |



RESEARCH
Department of Health and Human Services
National Institutes of Health

Notice of Award



NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

SECTION I – AWARD DATA – 5R01AI170633-04

Principal Investigator(s):

Karl Munger, PHD

Award e-mailed to: research_noas@tufts.edu

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$418,426 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to TUFTS UNIVERSITY BOSTON in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI170633. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Robert Kirker
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)

| | |
|---|-----------|
| Salaries and Wages | \$162,030 |
| Fringe Benefits | \$32,471 |
| Personnel Costs (Subtotal) | \$194,501 |
| Materials & Supplies | \$45,000 |
| Travel | \$2,000 |
| Other | \$12,454 |
| Publication Costs | \$2,000 |
| | |
| Federal Direct Costs | \$255,955 |
| Federal F&A Costs | \$162,471 |
| Approved Budget | \$418,426 |
| Total Amount of Federal Funds Authorized (Federal Share) | \$418,426 |
| TOTAL FEDERAL AWARD AMOUNT | \$418,426 |
| | |
| AMOUNT OF THIS ACTION (FEDERAL SHARE) | \$418,426 |

| SUMMARY TOTALS FOR ALL YEARS (for this Document Number) | | |
|---|------------|-------------------|
| YR | THIS AWARD | CUMULATIVE TOTALS |
| 4 | \$418,426 | \$418,426 |
| 5 | \$418,426 | \$418,426 |

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

Payment System Identifier: 1042103634A5
Document Number: RAI170633A
PMS Account Type: P (Subaccount)
Fiscal Year: 2026

| IC | CAN | 2026 | 2027 |
|----|---------|-----------|-----------|
| AI | 8472350 | \$418,426 | \$418,426 |

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: M34A / **OC:** 41025 / **Released:** 06/04/2026
Award Processed: 06/16/2026 12:19:16 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5R01AI170633-04

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – STANDARD TERMS AND CONDITIONS – 5R01AI170633-04

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 2 CFR Part 200.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the

definition of “Research and Development” at 2 CFR Part 200. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01A1170633. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Through acceptance of this award, recipient, and through implementation of this provision by recipient to each recipient investigator conducting work under this award, hereby grants to NIH a royalty-free, nonexclusive, and irrevocable right to reproduce, publish, or otherwise use for federal purposes and to authorize others to do so, all Author Accepted Manuscripts that result from this award, which includes making Author Accepted Manuscripts publicly available in PubMed Central upon the Official Date of Publication, in accordance with the 2024 NIH Public Access Policy.

Recipients must administer the project in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age, and comply with applicable conscience protections. The recipient will comply with applicable laws that prohibit discrimination on the basis of sex, which includes discrimination on the basis of gender identity, sexual orientation, and pregnancy. Compliance with these laws requires taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/>.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals, see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov>.
- For information on an institution’s specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
- HHS funded health and education programs must be administered in an environment free of sexual harassment; see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see <https://grants.nih.gov/grants/policy/harassment.htm>.
- For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and <https://www.hhs.gov/conscience/religious-freedom/index.html>.

In accordance with the regulatory requirements provided at 2 CFR Part 200, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management

(SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system that is found in [SAM.gov](https://sam.gov). Full reporting requirements and procedures are found in 2 CFR Part 200. This term does not apply to NIH fellowships.

Use of Supplies and Services for Harm Reduction Activities

For NIH awards that involve substance abuse, recipients are prohibited from using Federal funds, directly or indirectly, including through cost sharing, matching funds, or subsequent reimbursement, to support so-called "harm reduction" or "safe consumption" efforts that facilitate illegal drug use. Grant funds may not be used to purchase, distribute, or support drug paraphernalia as defined by law. This includes, but is not limited to, syringes or needles for illicit drug injection; pipes or supplies for safer smoking kits; fentanyl test strips or any other substance test kits, including xylazine and medetomidine test strips*; distribute any other drug paraphernalia or supplies that promote or facilitate drug use not listed here; purchase or distribute any other drug paraphernalia or supplies that promote or facilitate drug use not listed as acceptable. See [Updated Funding Guidance for Recipients on Supplies and Services](#).

Funds also may not support overdose hotlines whose primary purpose is to enable drug use by providing real-time virtual or phone-based accompaniment. These restrictions do not prohibit funding for legally permissible, evidence-based activities, such as the distribution of life-saving overdose prevention and response services, including purchase/distribution of naloxone or nalmefene and/or other infectious disease prevention services.

Failure to comply with the programmatic requirements outlined in the link above, (which provides updated guidance for recipients on the supplies and services previously defined under harm reduction that can be supported with NIH funding), may result in enforcement actions consistent with the [NIH Grants Policy Statement - 8/8.5.2](#), [2 CFR 200.339](#) and [2 CFR 200.340](#), and the terms and conditions of this award.

*This prohibition does not apply to law enforcement, emergency medical services, public health officials, or healthcare professionals using drug testing technologies in the regular course of discharging their professional duties, or as specifically authorized by the program statute. Also, this prohibition does not apply to the following awards: Training Grants, Fellowship Awards, Construction and Modernization Awards, Instrumentation Awards, Small Business Innovation Research/Small Business Technology Transfer Awards.

Treatment of Program Income:

Additional Costs

Termination. This award is subject to the termination provisions at 2 CFR 200.340. Pursuant to 2 CFR 200.340, the recipient agrees by accepting this award that continued funding for the award is contingent upon the availability of appropriated funds, recipient satisfactory performance, compliance with the Terms and Conditions of the award, and may also otherwise be terminated, to the extent authorized by law, if the agency determines that the award no longer effectuates program goals or agency priorities in line with 2 CFR 200.340(a)(4).

SECTION IV – AI SPECIFIC AWARD CONDITIONS – 5R01AI170633-04

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

Commitment overlap is not permitted, and occurs when an individual's time commitment exceeds 100 percent (i.e., 12 person months), whether or not salary support is requested. Therefore, no individual's time commitment may exceed 100 percent (i.e., 12 person months). Reductions in NIH support due to commitment overlap must be made in accordance with NIH policy as outlined in the NIH Grants Policy Statement.

SPREADSHEET SUMMARY**AWARD NUMBER:** 5R01AI170633-04**INSTITUTION:** TUFTS UNIVERSITY BOSTON

| Budget | Year 4 | Year 5 |
|----------------------------|-----------|-----------|
| Salaries and Wages | \$162,030 | \$162,030 |
| Fringe Benefits | \$32,471 | \$32,471 |
| Personnel Costs (Subtotal) | \$194,501 | \$194,501 |
| Materials & Supplies | \$45,000 | \$45,000 |
| Travel | \$2,000 | \$2,000 |
| Other | \$12,454 | \$12,454 |
| Publication Costs | \$2,000 | \$2,000 |
| TOTAL FEDERAL DC | \$255,955 | \$255,955 |
| TOTAL FEDERAL F&A | \$162,471 | \$162,471 |
| TOTAL COST | \$418,426 | \$418,426 |

| Facilities and Administrative Costs | Year 4 | Year 5 |
|-------------------------------------|-----------|-----------|
| F&A Cost Rate 1 | 65% | 65% |
| F&A Cost Base 1 | \$249,955 | \$249,955 |
| F&A Costs 1 | \$162,471 | \$162,471 |